SAN DIEGO, Sept. 7, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that setrobuvir (ANA598), the Company's direct-acting antiviral (DAA) currently in Phase IIb development for hepatitis C, has been selected as one of Windhover's Top 10 Most Interesting Infectious Disease Projects to Watch.
"We are honored to have setrobuvir identified as a Top 10 infectious disease project," said Kevin Eastwood, Anadys' Senior Vice President of Corporate Development. "This recognition reflects the scarcity of later-stage development assets in hepatitis C and the strong desire on the part of companies to assemble combination regimens to treat this disease. With a readout next month of the 12-week data from an ongoing Phase IIb trial, Anadys has positioned setrobuvir as a well-characterized agent, ideally suited to complement other DAAs as the treatment of HCV evolves to a DAA combination treatment paradigm."
Setrobuvir was selected by independent experts at Windhover Information and Herndon Company. The selection criteria included the breadth of business development opportunities, the current size and growth of the targeted market, and the strength of science underlying the program. Many assets selected in this manner by Windhover in prior years have been the focus of subsequent attractive business transactions.
As a selected company, Anadys will present at Windhover's 6th Annual Therapeutic Area Partnerships conference November 30-December 2, 2011 in Boston, MA. Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology, and medical device industries.
About setrobuvir in HCV
Setrobuvir, the Company's wholly-owned direct-acting antiviral or DAA, is an HCV RNA polymerase inhibitor that belongs to a chemical class referred to as non-nuc
|SOURCE Anadys Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved